MY103956A - Pharmaceutical compositions containing anthracycline glycosides - Google Patents

Pharmaceutical compositions containing anthracycline glycosides

Info

Publication number
MY103956A
MY103956A MYPI88001588A MYPI19881588A MY103956A MY 103956 A MY103956 A MY 103956A MY PI88001588 A MYPI88001588 A MY PI88001588A MY PI19881588 A MYPI19881588 A MY PI19881588A MY 103956 A MY103956 A MY 103956A
Authority
MY
Malaysia
Prior art keywords
hydroxy
benzoic acid
pharmaceutical compositions
weight
compositions containing
Prior art date
Application number
MYPI88001588A
Other languages
English (en)
Inventor
Gambini Luciano
Gatti Gaetono
Oldani Diego
Confalonieri Carlo
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MY103956A publication Critical patent/MY103956A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI88001588A 1984-10-22 1988-12-30 Pharmaceutical compositions containing anthracycline glycosides MY103956A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848426672A GB8426672D0 (en) 1984-10-22 1984-10-22 Pharmaceutical compositions
DE3536896A DE3536896C2 (de) 1984-10-22 1985-10-16 Lyophilisiertes, ein Anthracyclinglycosid enthaltendes pharmazeutisches Präparat und Verfahren zur Herstellung einer sterilen injizierbaren Lösung hieraus

Publications (1)

Publication Number Publication Date
MY103956A true MY103956A (en) 1993-10-30

Family

ID=10568553

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI88001588A MY103956A (en) 1984-10-22 1988-12-30 Pharmaceutical compositions containing anthracycline glycosides

Country Status (35)

Country Link
US (4) US4675311A (enEXAMPLES)
JP (1) JPH0611700B2 (enEXAMPLES)
KR (1) KR920005813B1 (enEXAMPLES)
CN (1) CN85107562B (enEXAMPLES)
AT (1) AT401345B (enEXAMPLES)
AU (1) AU572003B2 (enEXAMPLES)
BE (1) BE903484A (enEXAMPLES)
BG (1) BG60934B2 (enEXAMPLES)
CA (1) CA1248453A (enEXAMPLES)
CH (1) CH667594A5 (enEXAMPLES)
CS (1) CS270421B2 (enEXAMPLES)
DE (1) DE3536896C2 (enEXAMPLES)
DK (1) DK165620C (enEXAMPLES)
ES (1) ES8605374A1 (enEXAMPLES)
FI (2) FI853913A7 (enEXAMPLES)
FR (1) FR2571966B1 (enEXAMPLES)
GB (2) GB8426672D0 (enEXAMPLES)
GR (1) GR852549B (enEXAMPLES)
HK (1) HK94390A (enEXAMPLES)
HU (1) HU197988B (enEXAMPLES)
IE (1) IE56992B1 (enEXAMPLES)
IL (1) IL76732A (enEXAMPLES)
IT (1) IT1186779B (enEXAMPLES)
MY (1) MY103956A (enEXAMPLES)
NL (1) NL191308C (enEXAMPLES)
NO (1) NO170616C (enEXAMPLES)
NZ (1) NZ213885A (enEXAMPLES)
PH (1) PH23982A (enEXAMPLES)
PT (1) PT81347B (enEXAMPLES)
RU (2) RU1836088C (enEXAMPLES)
SE (1) SE467520B (enEXAMPLES)
SG (1) SG80290G (enEXAMPLES)
UA (2) UA19169A (enEXAMPLES)
YU (1) YU46160B (enEXAMPLES)
ZA (1) ZA858033B (enEXAMPLES)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124318A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124317A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5977082A (en) * 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
DE3741037A1 (de) * 1986-12-05 1988-06-09 Erba Farmitalia Injizierbare, gebrauchsfertige loesungen, welche ein antitumor-anthracyclinglycosid enthalten
JP2603480B2 (ja) * 1987-08-05 1997-04-23 住友製薬株式会社 安定化されたアンスラサイクリン系製剤
DE3801178A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierte trockenzubereitung zytostatisch wirksamer anthracyclin-antibiotika und verfahren zu ihrer herstellung
US6300362B1 (en) 1990-07-25 2001-10-09 Novartis Ag (Formerly Sandoz Ltd.) Stabilized pharmaceutical compositions comprising acid donors
DE69737510T2 (de) 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
RU2292216C2 (ru) * 2000-10-31 2007-01-27 Фарма Мар, С.А. Кахалалид f
KR100970528B1 (ko) 2002-02-22 2010-07-16 쉐링 코포레이션 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법
DK1474995T3 (da) * 2003-05-06 2013-02-18 Gumlink As Fremgangsmåde til fremstilling af tyggegummigranulater, et gummisammensætningsekstruder- og granuleringssystem og et tyggegummiprodukt
US20090099346A1 (en) * 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride
CN100412084C (zh) * 2003-07-02 2008-08-20 獀洛克斯股份有限公司 热稳定的结晶盐酸表柔比星及其制造方法
SI2263694T1 (sl) * 2003-09-25 2013-09-30 Astellas Pharma Inc. Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
US7388083B2 (en) * 2005-03-07 2008-06-17 Solux Corporation Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics
JP2008513519A (ja) * 2005-05-11 2008-05-01 シコール インコーポレイティド 安定した凍結乾燥されたアントラサイクリングリコシド
EP1921919B1 (en) 2005-07-14 2012-04-04 Lithera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
CN101331147B (zh) * 2005-12-13 2011-11-30 苏洛克股份有限公司 用于制备4-脱甲基柔红霉素的方法
US8802830B2 (en) * 2005-12-20 2014-08-12 Solux Corporation Synthesis of epirubicin from 13-dihydrodaunorubicine
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
EP2152312B1 (en) * 2007-05-16 2014-12-31 KTB Tumorforschungsgesellschaft mbH Low-viscous anthracycline formulation
US8227430B2 (en) 2007-09-04 2012-07-24 Meiji Seika Pharma Co., Ltd Injectable, injection solution, and injection kit preparation
US20100234314A1 (en) * 2007-10-26 2010-09-16 Pfizer Inc. Idarubicin for the treatment of lymphoma in a dog
US8357785B2 (en) * 2008-01-08 2013-01-22 Solux Corporation Method of aralkylation of 4′-hydroxyl group of anthracylins
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CN102869363A (zh) * 2010-01-15 2013-01-09 利赛拉公司 冻干的块状制剂
UA111822C2 (uk) 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
DE102011103751A1 (de) 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Kristallisierung von Epirubicinhydrochlorid
DE102011111991A1 (de) * 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
DK2931042T3 (da) 2012-12-13 2021-06-07 Cytrx Corp Anthracyclinformuleringer
CA2912908C (en) 2013-06-05 2021-06-08 Cytrx Corporation Cytotoxic agents comprising covalently protein binding groups for treating brain cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4039663A (en) * 1975-03-19 1977-08-02 Societa' Farmaceutici Italia S.P.A. Daunomycins, process for their uses and intermediates
GB1506200A (en) * 1975-04-30 1978-04-05 Farmaceutici Italia Glycosides
GB1567456A (en) * 1976-11-16 1980-05-14 Farmaceutici Italia Daunomycin derivatives
US4177264A (en) * 1977-10-17 1979-12-04 Sri International N-benzyl anthracyclines
GB2007645B (en) * 1977-10-17 1982-05-12 Stanford Res Inst Int Benzyl anthracyclines and pharmaceutical compositions containing them
JPS563851A (en) * 1979-06-22 1981-01-16 Matsushita Electric Works Ltd Fireplace in floor
JPS5756494A (en) * 1980-09-22 1982-04-05 Microbial Chem Res Found New anthracyclin derivative
US4325947A (en) * 1981-05-12 1982-04-20 Farmitalia Carlo Erba S.P.A. 4-Demethoxy-4'-deoxydoxorubicin
IT1210476B (it) * 1981-05-28 1989-09-14 Erba Farmitalia Antracicline.
US4438105A (en) * 1982-04-19 1984-03-20 Farmaitalia Carlo Erba S.P.A 4'-Iododerivatives of anthracycline glycosides
FI75834C (fi) * 1982-05-24 1988-08-08 Erba Farmitalia Foerfarande foer framstaellning av antracyklinglykosidfoereningar.
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
CA1248944A (en) * 1982-09-28 1989-01-17 Gareth J. Thomas Anthracycline glycosides
JPS5982395A (ja) * 1982-11-02 1984-05-12 Microbial Chem Res Found アントラサイクリン化合物、その製造法およびその用途
GR79729B (enEXAMPLES) * 1982-12-20 1984-10-31 Univ Ohio State Res Found
JPS6092212A (ja) * 1983-10-26 1985-05-23 Kyowa Hakko Kogyo Co Ltd ドキソルビシン塩の製剤
US4537882A (en) * 1984-05-10 1985-08-27 Ohio State University 4-Demethoxy-3'-desamino-2'-halo-anthracycline and pharmaceutical composition containing same

Also Published As

Publication number Publication date
SG80290G (en) 1990-11-23
CN85107562B (zh) 1988-06-01
ZA858033B (en) 1986-06-25
FI86252C (fi) 1992-08-10
DK165620B (da) 1992-12-28
NO170616C (no) 1992-11-11
ES8605374A1 (es) 1986-03-16
NL191308C (nl) 1995-05-16
FI854035A0 (fi) 1985-10-16
PT81347A (en) 1985-11-01
NL191308B (nl) 1994-12-16
RU1836088C (ru) 1993-08-23
FR2571966A1 (fr) 1986-04-25
CN85107562A (zh) 1986-07-23
RU2101018C1 (ru) 1998-01-10
UA19169A (uk) 1997-12-25
IE852593L (en) 1986-04-22
IE56992B1 (en) 1992-02-26
AU4880585A (en) 1986-05-01
NO170616B (no) 1992-08-03
CH667594A5 (de) 1988-10-31
AU572003B2 (en) 1988-04-28
SE8504945D0 (sv) 1985-10-21
SE8504945L (sv) 1986-04-23
NL8502869A (nl) 1986-05-16
IL76732A (en) 1989-07-31
DE3536896C2 (de) 1996-11-14
KR860003014A (ko) 1986-05-19
FI853913A0 (fi) 1985-10-08
GB8426672D0 (en) 1984-11-28
YU164485A (en) 1987-10-31
HK94390A (en) 1990-11-23
AT401345B (de) 1996-08-26
FI853913A7 (fi) 1986-04-23
YU46160B (sh) 1993-05-28
GB8525709D0 (en) 1985-11-20
IL76732A0 (en) 1986-02-28
DE3536896A1 (de) 1986-04-24
BE903484A (fr) 1986-04-21
JPS61246129A (ja) 1986-11-01
NO854194L (no) 1986-04-23
US4675311A (en) 1987-06-23
SE467520B (sv) 1992-08-03
CA1248453A (en) 1989-01-10
ES547578A0 (es) 1986-03-16
US5091373A (en) 1992-02-25
PH23982A (en) 1990-02-09
KR920005813B1 (ko) 1992-07-20
DK165620C (da) 1993-06-01
CS756585A2 (en) 1989-11-14
BG60934B2 (bg) 1996-06-28
ATA303285A (de) 1996-01-15
HUT40759A (en) 1987-02-27
GB2165751A (en) 1986-04-23
CS270421B2 (en) 1990-06-13
FI86252B (fi) 1992-04-30
IT8522507A0 (it) 1985-10-16
US4840938A (en) 1989-06-20
UA34419C2 (uk) 2001-03-15
DK481585D0 (da) 1985-10-21
PT81347B (pt) 1987-11-11
DK481585A (da) 1986-04-23
FI854035L (fi) 1986-04-23
IT1186779B (it) 1987-12-16
NZ213885A (en) 1988-05-30
GR852549B (enEXAMPLES) 1986-02-24
HU197988B (en) 1989-07-28
US5091372A (en) 1992-02-25
JPH0611700B2 (ja) 1994-02-16
FR2571966B1 (fr) 1988-04-15
GB2165751B (en) 1988-08-17

Similar Documents

Publication Publication Date Title
MY103956A (en) Pharmaceutical compositions containing anthracycline glycosides
KR910004582A (ko) 티아졸 유도체, 이의 제조방법 및 이를 함유하는 약학조성물
AU3132489A (en) Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
IL92730A (en) 2-aminopyrimidinone derivatives, their preparation and pharmaceutical compositions containing them
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
MD1233B1 (en) Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof
SE8402560L (sv) Farmaceutisk komposition
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
PT85591A (en) Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
IL89199A0 (en) 3'-deamino-4'-deoxy-4'-amino anthracyclines,their preparation and pharmaceutical compositions containing them
IE821779L (en) Pyridazine derivative.
UA37311C2 (uk) Засіб для лікування статевої дисфункції і фармацевтичний препарат
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
ES8404360A1 (es) Un procedimiento para preparar compuestos de cefem.
IE40957L (en) 4- o-ó,d-glucopyranosyl -6-o-ó,d- xylohexopyranosyl -2-¹deoxystreptamine
GB1506664A (en) Antiviral compositions
IL85822A (en) 7-alkanesulphonoamido-1,2,4,5-tetrahydro-3h-3-benzazepine derivatives,their preparation and pharmaceutical compositions containing them
EP0136463B1 (en) Injectable therapeutic compositions containing stable s-adenosyl-l-methionine salts
CA2016470A1 (en) Pharmaceutical preparation and method of treatment for liver dysfunction
NO903058L (no) Farmasoeytisk preparat med forbedret absorberbarhet.
JPS57200361A (en) "indomethacin(r)" pharmaceutical with low irritant action
WO1990003172A3 (en) Bile acids for treatment of viral infections
IL66473A0 (en) Aminoglycoside derivatives,their production and pharmaceutical compositions containing them
GB1214247A (en) N,n'-bis-(diphenylalkyl)-alkylene diamines